Novavax (NVAX) Misses Q4 EPS by $1.09

Novavax (NASDAQ: NVAX) reported Q4 EPS of ($2.28), $1.09 worse than the analyst estimate of ($1.19). Revenue for the quarter came in at $357 million versus the consensus estimate of $383.14 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
• ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance